VBI Vaccines Inc (NASDAQ:VBIV) major shareholder Life Sciences Maste Perceptive purchased 1,000,000 shares of the company’s stock in a transaction on Monday, June 17th. The stock was acquired at an average price of $0.62 per share, with a total value of $620,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of VBI Vaccines stock traded down $0.01 on Thursday, reaching $0.86. The company’s stock had a trading volume of 494,508 shares, compared to its average volume of 1,147,524. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.99 and a quick ratio of 1.94. VBI Vaccines Inc has a 52-week low of $0.57 and a 52-week high of $3.00. The firm has a market capitalization of $84.97 million, a P/E ratio of -0.89 and a beta of 0.45. The business has a 50-day simple moving average of $1.45.
VBI Vaccines (NASDAQ:VBIV) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.15) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.15). VBI Vaccines had a negative return on equity of 75.01% and a negative net margin of 1,864.77%. The firm had revenue of $0.36 million during the quarter, compared to analysts’ expectations of $0.20 million. Research analysts expect that VBI Vaccines Inc will post -0.43 earnings per share for the current year.
A number of research analysts have recently commented on VBIV shares. Oppenheimer set a $68.00 target price on Biohaven Pharmaceutical and gave the company a “buy” rating in a research report on Wednesday, June 19th. Zacks Investment Research downgraded Farmers & Merchants Bancorp, Inc. (OH) from a “hold” rating to a “strong sell” rating in a research report on Thursday, May 9th. Finally, BMO Capital Markets reiterated a “market perform” rating and issued a C$36.00 target price on shares of NFI Group in a research note on Tuesday, June 18th.
VBI Vaccines Company Profile
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.
Featured Article: How is Preferred Stock Different from Common Stock?
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.